NICE Yes For Lynparza In England May Have 'Huge Impact' For Ovarian Cancer
AstraZeneca and MSD's Lynparza can now be paid for through England’s Cancer Drugs Fund for use in women with advanced BRCA-mutated ovarian cancer when their disease is newly diagnosed and when the drug may have the potential to cure their disease.
You may also be interested in...
NICE Draft Guidance: Rejects Keytruda In Head & Neck Cancer, Xospata In AML
A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited by potential breakthroughs that health technology assessment has become an exacting filter for new medicines to pass through.
Scottish HTA body OKs Lynparza For Earlier Use In Ovarian Cancer
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.
New Price Helps Secure Funding For Rubraca In England
Clovis Oncology’s ovarian cancer treatment Rubraca is the latest PARP inhibitor to get the all-clear from the health technology assessment body, NICE.